Unnamed: 0,title,date,stock,sentiment
413473.0,Eagle Pharmaceuticals: Q1 Earnings Insights,2020-05-11 08:14:00-04:00,EGRX,neutral
413474.0,"Eagle Pharmaceuticals Q1 EPS $0.84 Beats $0.57 Estimate, Sales $46.020M Miss $51.100M Estimate",2020-05-11 07:04:00-04:00,EGRX,negative
413475.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,EGRX,neutral
413476.0,Eagle Pharma Says it Plans to Request a Meeting with the FDA to Advance its EA-114 Program,2020-05-04 06:53:00-04:00,EGRX,neutral
413477.0,UPDATE: Court In Eagle Pharma Case Upheld Asserted Patent Claims As Valid And Found That The Defendants' Proposed ANDA Products Would Infringe Claims,2020-04-28 06:55:00-04:00,EGRX,neutral
413478.0,"Court Issues Patent Litigation Decision For Eagle Pharmaceuticals, Inc. And Teva Pharmaceutical Industries Ltd. For BENDEKA (bendamustine hydrochloride injection)",2020-04-28 06:53:00-04:00,EGRX,negative
413479.0,35 Stocks Moving in Monday's Pre-Market Session,2020-04-20 07:20:00-04:00,EGRX,neutral
413480.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,EGRX,neutral
413481.0,Eagle Pharma Reports Lab Test Results Showing In Vitro Antiviral Activity Of RYANODEX Against Coronavirus,2020-04-16 06:53:00-04:00,EGRX,neutral
413482.0,"Eagle Pharmaceuticals Announces $160M Buyback, Which Replaces Existing Buyback",2020-03-17 07:10:00-04:00,EGRX,neutral
413483.0,Stocks That Hit 52-Week Lows On Friday,2020-03-13 11:13:00-04:00,EGRX,negative
413484.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,EGRX,negative
413485.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,EGRX,negative
413486.0,Stocks That Hit 52-Week Lows On Friday,2020-03-06 11:22:00-05:00,EGRX,negative
413487.0,"The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study",2020-03-06 08:49:00-05:00,EGRX,negative
413488.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,EGRX,positive
413489.0,"Cantor Fitzgerald Maintains Neutral on Eagle Pharmaceuticals, Lowers Price Target to $46",2020-03-02 12:12:00-05:00,EGRX,negative
413490.0,"Eagle Pharmaceuticals Q4 EPS $0.49, Inline, Sales $48.258M Miss $49.07M Estimate",2020-03-02 06:51:00-05:00,EGRX,negative
413491.0,Eagle Pharmaceuticals Receives Final FDA Approval For PEMFEXY,2020-02-10 09:56:00-05:00,EGRX,positive
413492.0,Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer's Disease in Collaboration With University of Pennsylvania,2020-01-13 06:57:00-05:00,EGRX,neutral
413493.0,Eagle Pharma Reports Resubmission Of New Drug Application For RYANODEX For Exertional Heat Stroke,2020-01-09 06:50:00-05:00,EGRX,neutral
413494.0,Tyme Technologies And Eagle Pharmaceuticals Announce Collaboration To Advance Oral SM-88 For Treatment Of Patients With Cancer; Tyme Entitled To Receive Total Of $40M In The Form Of Upfront Payment And Milestones,2020-01-07 07:23:00-05:00,EGRX,negative
413495.0,Eagle Pharma Granted Orphan Drug Designation for RYANODEX for Treatment of Organophosphate Exposure by the FDA,2019-12-16 06:50:00-05:00,EGRX,positive
413496.0,"Eagle Pharma Has Reached Settlement with Lilly related To PEMFEXY; All Claims Released, Allows For Initial Entry Of PEMFEXY Into Market On Feb. 1, 2022, Uncapped Entry Apr. 1, 2022",2019-12-13 14:56:00-05:00,EGRX,positive
413497.0,Eagle Pharmaceuticals Says Will Be Submitting NDA For RYANODEX 'Shortly' Following Additional Communications With FDA,2019-12-10 07:11:00-05:00,EGRX,neutral
413498.0,Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate,2019-12-09 06:53:00-05:00,EGRX,negative
413499.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,EGRX,neutral
413500.0,"Eagle Pharmaceuticals Q3 Adj. EPS $0.27 Misses $0.57 Estimate, Sales $41.147M Miss $48.49M Estimate",2019-11-12 06:52:00-05:00,EGRX,negative
413501.0,Stocks That Hit 52-Week Highs On Monday,2019-11-04 14:43:00-05:00,EGRX,neutral
413502.0,Stocks That Hit 52-Week Highs On Friday,2019-10-25 12:47:00-04:00,EGRX,neutral
413503.0,"The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch",2019-10-16 07:06:00-04:00,EGRX,positive
413504.0,Eagle Pharma Subsidiary Submits a New Drug Application for TREAKISYM,2019-10-07 06:55:00-04:00,EGRX,neutral
413505.0,"Eagle Pharmaceuticals Earlier Reported Q2 EPS $0.84 Beats $0.83 Estimate, Sales $56.702M Beat $53.59M Estimate",2019-08-08 11:24:00-04:00,EGRX,neutral
413506.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,EGRX,neutral
413507.0,Eagle Pharma Announces Clinical Development Plan to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor (ER)-Positive Breast Cancer,2019-08-05 06:56:00-04:00,EGRX,negative
413508.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,EGRX,neutral
413509.0,"Eagle Pharmaceuticals Q1 Adj. EPS $1.01 Beats $0.84 Estimate, Sales $49.8M Beat $48.15M Estimate",2019-05-07 06:55:00-04:00,EGRX,neutral
413510.0,Eagle Pharmaceuticals Announces Results Of Study Conducted In Partnership US Military To Evaluate Neuroprotective Effects Of RYANODEX For Treatment Of Nerve Agent Exposure; Results Showed Statistically Significant Lower Incidence Of Brain Damage Compared,2019-05-07 06:52:00-04:00,EGRX,negative
413511.0,"Jim Cramer Weighs In On Micron, Halliburton And More",2019-04-25 08:14:00-04:00,EGRX,neutral
413512.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,EGRX,positive
413513.0,Eagle Pharma Establishes a Billing Code for BELRAPZO 500mL Injection,2019-04-22 06:51:00-04:00,EGRX,neutral
413514.0,Eagle Pharma Increases its Royalty Payment Split with Teva Pharma,2019-04-15 06:53:00-04:00,EGRX,neutral
413515.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,EGRX,positive
413516.0,"Eagle Pharmaceuticals Q4 Adj. EPS $1.20 Beats $1.16 Estimate, Sales $56.1M Beat $54.17M Estimate",2019-02-28 06:54:00-05:00,EGRX,neutral
413517.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,EGRX,neutral
413518.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,EGRX,negative
413519.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,EGRX,negative
413520.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,EGRX,negative
413521.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,EGRX,neutral
413522.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,EGRX,negative
413523.0,Eagle Pharmaceuticals Reports 'Positive' Results Of Pre-clinical Study Conducted To Evaluate Effects Of RYANODEX In Acute Radiation Syndrome,2018-11-27 06:51:00-05:00,EGRX,neutral
413524.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,EGRX,negative
413525.0,"Eagle Pharmaceuticals Q3 Adj. EPS $1.18 Down From $1.22 YoY, Sales $51.337M Down From $63.021M YoY",2018-11-01 08:19:00-04:00,EGRX,neutral
413526.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,EGRX,negative
413527.0,8 Biggest Price Target Changes For Wednesday,2018-10-31 10:02:00-04:00,EGRX,neutral
413528.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,EGRX,negative
413529.0,"PiperJaffray Downgrades Eagle Pharmaceuticals to Neutral, Lowers Price Target to $54",2018-10-31 06:33:00-04:00,EGRX,negative
413530.0,64 Biggest Movers From Yesterday,2018-10-31 05:00:00-04:00,EGRX,neutral
413531.0,55 Stocks Moving In Tuesday's Mid-Day Session,2018-10-30 13:32:00-04:00,EGRX,neutral
413532.0,Eagle Pharmaceuticals Sees Q3 Adj. EPS $1.18 vs $1.38 Est.,2018-10-30 06:54:00-04:00,EGRX,neutral
413533.0,Eagle Pharmaceuticals Commences $50M Buyback As Part Of New $150M Share Repurchase Authorization,2018-10-30 06:53:00-04:00,EGRX,positive
413534.0,Eagle Pharmaceuticals Enters Into Agreement with USAMRICD To Evaluate Neuroprotective Effects Of RYANODEX Secondary To Nerve Agent Exposure,2018-10-03 07:01:00-04:00,EGRX,positive
413535.0,Eagle Pharma Names David Pernock COO,2018-09-26 16:30:00-04:00,EGRX,neutral
413536.0,"Cantor Fitzgerald Maintains Overweight on Eagle Pharmaceuticals, Lowers Price Target to $80",2018-09-21 08:44:00-04:00,EGRX,negative
413537.0,62 Biggest Movers From Yesterday,2018-08-31 05:19:00-04:00,EGRX,neutral
413538.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-08-30 12:44:00-04:00,EGRX,neutral
413539.0,"Eagle Pharma Reports Completion Of Enrollment For Second Safety, Efficacy Study At Hajj To Evaluate RYANODEX For Exertional Heat Stroke",2018-08-30 07:03:00-04:00,EGRX,positive
413540.0,"Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA, Which Is Now Protected By 16 Patents Running From 2026-2033",2018-08-22 09:04:00-04:00,EGRX,positive
413541.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,EGRX,negative
413542.0,"Eagle Pharmaceuticals Q2 EPS $0.95 Beats $0.80 Estimate, Sales $59.3M Beat $51.23M Estimate",2018-08-07 06:52:00-04:00,EGRX,neutral
413543.0,Stocks Which Set New 52-Week Highs Friday,2018-07-23 11:08:00-04:00,EGRX,neutral
413544.0,Stocks Which Set New 52-Week High Yesterday,2018-07-20 09:05:00-04:00,EGRX,neutral
413545.0,"Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2",2018-07-20 07:53:00-04:00,EGRX,positive
413546.0,"Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial",2018-07-12 08:37:00-04:00,EGRX,neutral
413547.0,Eagle Pharma's BENDEKA is Granted 7 Year Orphan Drug Exclusivity by the FDA,2018-07-09 07:10:00-04:00,EGRX,positive
413548.0,"Eagle Pharma Reports New Patent Issued For BENDEKA, Is Now Protected By 15 Patents Running From 2026-2033",2018-07-03 08:31:00-04:00,EGRX,positive
413549.0,"Cantor Fitzgerald Initiates Coverage On 8 Pharma/Biotech Stocks After Hours: 7 With Overweight, 1 With Neutral Rating",2018-06-11 16:54:00-04:00,EGRX,negative
413550.0,Eagle Pharma Shares Down 1% Despite Earlier News Court Issued Decision In Favor Of Co. Related To Orphan Drug Exclusivity For BENDEKA; Mizuho Earlier Upgraded Stock From Underperform To Neutral,2018-06-11 12:54:00-04:00,EGRX,positive
413551.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-11 09:32:00-04:00,EGRX,neutral
413552.0,Court Issues Decision In Favor Of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine hydrochloride injection); FDA Will Be Unable To Approve Any Drug Applications Referencing BENDEKA Until ODE Expires In 2022,2018-06-11 06:52:00-04:00,EGRX,positive
413553.0,Eagle Pharmaceuticals Shares Up 7.9% After Hearing Word That Court Has Said Co. Should Receive Orphan Drug Designation For Bendeka,2018-06-08 15:59:00-04:00,EGRX,positive
413554.0,Eagle Pharma Shares Spike Following Word Court Has Said Should Receive Orphan Drug Designation For Bendeka,2018-06-08 15:10:00-04:00,EGRX,positive
413555.0,"Eagle Pharma Shares Spike 6.4% Over Last Min., Now Up 7.3% For Session",2018-06-08 15:01:00-04:00,EGRX,positive
413556.0,Eagle Pharma Shares Up 2% Wed.; Co. Earlier Announced Granting Of Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500ml Admixture; Co. Will Ship Product Immediately,2018-05-16 11:13:00-04:00,EGRX,positive
413557.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,EGRX,neutral
413558.0,"Eagle Pharmaceuticals Q1 EPS $0.53 Down From $1.64 YoY, Sales $46.6M Miss $50.29M Estimate",2018-05-10 06:57:00-04:00,EGRX,negative
413559.0,"Deutsche Bank Health Care Conference Concludes Today, Presenters Include: Cerus, ImmunoGen, and Eagle Pharmaceuticals",2018-05-09 07:09:00-04:00,EGRX,positive
413560.0,"Endo Int'l Receives Notification Eagle Pharma Has Submitted ANDA to FDA Seeking Approval For A Generic Version of Vasostrict; Endo Says It Intends to 'Vigorously Protect Its Intellectual Property,' Including Potentially Filing Patent Infringement Lawsuit",2018-04-17 16:34:00-04:00,EGRX,positive
413561.0,Eagle Pharma Reports ANDA For Vasopressin Has Been Accepted For Filing By FDA,2018-04-16 07:05:00-04:00,EGRX,positive
413562.0,"UPDATE: Eagle Pharma Says Patent Number 9,925,263 Will Expire Mar. 2036, Related To A Technology Which Allows For The Formulation Of Antibodies At High Concentration",2018-03-27 08:40:00-04:00,EGRX,positive
413563.0,Eagle Pharmaceuticals Announces New Patent for Eagle Biologics,2018-03-27 08:30:00-04:00,EGRX,neutral
413564.0,38 Biggest Movers From Yesterday,2018-02-27 04:58:00-05:00,EGRX,neutral
413565.0,Eagle Pharmaceuticals Shares Down 8.5% Following Q4 Sales Miss But Inline Earnings,2018-02-26 15:59:00-05:00,EGRX,positive
413566.0,"Eagle Pharma Reports Q4 Adj. EPS $1.00 vs $1.00 Est., Sales $46.79M vs $52.91M Est.",2018-02-26 06:51:00-05:00,EGRX,neutral
413567.0,"RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte",2018-02-21 07:14:00-05:00,EGRX,neutral
413568.0,Eagle Pharma Granted a Patent for RYANODEX,2018-02-07 07:35:00-05:00,EGRX,positive
413569.0,Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant,2017-12-07 09:15:00-05:00,EGRX,neutral
413570.0,"Piper Jaffray Healthcare Conference Concludes Today, Presenters Include: Kadmon, Ignyta, Eagle Pharmaceuticals, Tandem Diabetes Care, DexCom, and Alnylam Pharmaceuticals",2017-11-29 09:30:00-05:00,EGRX,positive
413571.0,"Jefferies 2107 London Healthcare Conference Begins Today, Presenters Include: Alkermes, Bristol-Myers, Immunogen, and Eagle Pharmaceuticals",2017-11-15 09:00:00-05:00,EGRX,neutral
413572.0,"Eagle Pharma Reports Q3 Adj. EPS $1.22 vs $0.80 Est., Sales $63M vs $50.9M Est.",2017-11-08 06:56:00-05:00,EGRX,neutral
413573.0,Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY,2017-10-27 15:02:00-04:00,EGRX,positive
413574.0,Eagle Pharma Issued a Patent for RYANODEX,2017-10-17 07:36:00-04:00,EGRX,neutral
413575.0,"Eagle Pharma Q2 Adj. EPS $0.49 vs $0.51 Est., Sales $50.11M vs $52.52M Est.",2017-08-09 06:55:00-04:00,EGRX,neutral
413576.0,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 09:20:00-04:00,EGRX,neutral
413577.0,Eagle Pharmaceuticals Shares Down 20.69% At $55.83/Share,2017-07-26 13:02:00-04:00,EGRX,positive
413578.0,Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application,2017-07-26 12:30:00-04:00,EGRX,neutral
413579.0,"UPDATE: Eagle Pharma Says 'NDA for RYANODEX was accepted for Priority Review, with review timelines within six months of the NDA submission. The PDUFA date was Sunday, July 23, 2017'",2017-07-25 09:23:00-04:00,EGRX,positive
413580.0,Eagle Pharma Offers Statement Related To RYANODEX Application PDUFA Date For Exertional Heat Stroke: Co. 'has not yet received correspondence from FDA',2017-07-25 09:22:00-04:00,EGRX,neutral
413581.0,"REMINDER: Eagle Pharmaceuticals NDA PDUFA Date For Ryanodex Is Sunday, 7/23",2017-07-21 08:40:00-04:00,EGRX,neutral
413582.0,Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days,2017-07-05 11:01:00-04:00,EGRX,neutral
413584.0,Eagle Pharmaceuticals Releases Investor Presentation,2017-06-08 06:19:00-04:00,EGRX,neutral
413585.0,"Bank Of America Health Care Conference Concludes Today; Presenters Include Boston Scientific, Humana, Universal Health, Chemed, Community Health, Eagle Pharma, Alnylam, Gilead, & Illumina",2017-05-18 08:53:00-04:00,EGRX,positive
413586.0,Eagle Pharma Announces Pete Meyers CFO,2017-05-15 06:50:00-04:00,EGRX,neutral
413587.0,"Eagle Pharma Q1 EPS $1.42 vs $1.42 Est, Sales $76.8M vs $70.4M Est",2017-05-08 06:54:00-04:00,EGRX,neutral
413588.0,"Deutsche Bank Health Care Conference Concludes Today, Presenters Include: Eagle Pharma, Foamix, Universal Health Services, NovoCure, & Bristol-Myers",2017-05-04 08:28:00-04:00,EGRX,positive
413589.0,Eagle Pharma Gets Priority FDA Review for Ryanodex NDA,2017-03-27 06:51:00-04:00,EGRX,neutral
413590.0,Eagle Pharma Reports 3 New Patents Issued for Bendeka,2017-03-21 08:01:00-04:00,EGRX,neutral
413591.0,"Hearing Mizuho Out Negative On Eagle Pharmaceuticals, Cautious On External Heat Stroke Product Launch, Reiterates Underperform",2017-03-17 09:39:00-04:00,EGRX,negative
413592.0,"Eagle Pharma Reports Q4 GAAP EPS $3.75 May Not Compare to $2.86 Est., Sales $81.1M vs $86.1M Est.",2017-03-01 06:54:00-05:00,EGRX,neutral
413593.0,Eagle Pharmaceuticals' Novel Pemetrexed NDA Accepted for Filing by the FDA,2017-02-28 09:05:00-05:00,EGRX,positive
413594.0,Eagle Pharmaceuticals Announces New Patents Issued for Bendeka,2017-02-21 09:36:00-05:00,EGRX,neutral
413595.0,Eagle Pharma Completes NDA for Ryanodex,2017-01-23 06:51:00-05:00,EGRX,neutral
413596.0,"The Market In 5 Minutes: Earnings Results, Conferences, Trump And More",2017-01-09 08:17:00-05:00,EGRX,neutral
413597.0,"Mizuho Downgrades Eagle Pharmaceuticals to Underperform, Lowers Target to $64.00",2017-01-09 06:24:00-05:00,EGRX,negative
413598.0,Eagle Pharmaceuticals' Pemetrexed NDA Submitted to FDA for Review,2017-01-03 06:50:00-05:00,EGRX,neutral
413599.0,Eagle Pharmaceuticals Names David Pernock Chief Commercial Officer,2016-12-19 08:01:00-05:00,EGRX,neutral
413600.0,Wall Street's M&A Chatter From November 11-13,2016-11-14 07:41:00-05:00,EGRX,neutral
413601.0,"Eagle Pharma to Acquire Arsia Therapeutics for $30M, Up to $18M Additional May Be Paid for Milestones",2016-11-11 07:01:00-05:00,EGRX,neutral
413602.0,Eagle Pharma Reports Initiation of Rolling Submission of NDA for Ryanodex in Exertional Heat Stroke,2016-11-11 06:55:00-05:00,EGRX,neutral
413603.0,"EAGLE PHARMACEUTICALS, INC.: SCHREIBER ALAIN (10%+) Sells 153,830 @ Avg Price: $79.29 (Form4",2016-11-09 18:20:00-05:00,EGRX,neutral
413604.0,"Eagle Pharma Q3 EPS $0.77 vs $0.65 Est, Revenue $37.8M vs $41.1M Est",2016-11-09 06:52:00-05:00,EGRX,neutral
413605.0,10 Stocks That Rallied Three Days On No News,2016-11-04 06:23:00-04:00,EGRX,negative
413606.0,"Mizuho Upgrades Eagle Pharmaceuticals, Inc. - Common Stock to Buy",2016-11-03 05:50:00-04:00,EGRX,neutral
413607.0,"William Blair Maintains Outperform on Eagle Pharmaceuticals, Inc. - Common Stock, Raises to $97.00",2016-11-02 10:48:00-04:00,EGRX,neutral
413608.0,"Teva, Eagle Announce CMS Establishes Unique J-Code for BENDEKA® (Bendamustine Hydrochloride) Injection",2016-11-02 09:34:00-04:00,EGRX,neutral
413609.0,Eagle Pharmaceuticals Announces Positive Initial Results of Animal Study Exploring Use of Ryanodex in MDMA Induced Hyperthermia Conducted at the National Institutes of Health,2016-10-31 07:00:00-04:00,EGRX,positive
413610.0,15 Biggest Mid-Day Gainers For Tuesday,2016-08-23 12:35:00-04:00,EGRX,neutral
413611.0,20 Stocks Moving In Tuesday's Pre-Market Session,2016-08-23 08:31:00-04:00,EGRX,neutral
413612.0,"S&P Dow Jones Indices Says 'Chemical Financial Set to Join S&P MidCap 400; Supervalu, Shoe Carnival and Eagle",2016-08-22 17:23:00-04:00,EGRX,positive
413613.0,18 Biggest Mid-Day Gainers For Tuesday,2016-08-09 12:44:00-04:00,EGRX,neutral
413614.0,22 Stocks Moving In Tuesday's Pre-Market Session,2016-08-09 08:48:00-04:00,EGRX,neutral
413615.0,Eagle Pharmaceuticals Reports Positive Outcome from FDA Meeting for Ryanodex for Exertional Heat Stroke NDA Submission; Says Reduced Future Ryanodex Royalty Obligations to Licensing Partner from 15% to 3% of Net Sales for Payment of $15M in Cash,2016-08-09 06:53:00-04:00,EGRX,positive
413616.0,"Eagle Pharma Q2 EPS $0.84 vs $0.71 est, Revenue $40.9M vs $40.8M est",2016-08-09 06:50:00-04:00,EGRX,neutral
413617.0,Eagle Pharma Names Michael Graves Chair,2016-07-05 07:03:00-04:00,EGRX,negative
413618.0,Hudson Executive Capital LP Reports 6.1% Stake in Eagle Pharmaceuticals in 13D,2016-06-27 16:07:00-04:00,EGRX,neutral
413619.0,Mid-Afternoon Market Update: Yelp Shares Gain Following Analyst Upgrade; Cypress Semiconductor Shares Drop,2016-06-20 14:30:00-04:00,EGRX,positive
413620.0,6 Biggest Mid-Day Losers For Monday,2016-06-20 13:00:00-04:00,EGRX,negative
413621.0,Mid-Day Market Update: Crude Oil Rises 2.5%; Epizyme Shares Drop,2016-06-20 12:11:00-04:00,EGRX,negative
413622.0,Mid-Morning Market Update: Markets Open Higher; Icahn Enterprises Raises Offer For Federal Mogul,2016-06-20 10:01:00-04:00,EGRX,neutral
413623.0,Mizuho Securities Downgrades Eagle Pharmaceuticals to Neutral,2016-06-20 08:00:00-04:00,EGRX,positive
413624.0,"UPDATE: Teva Says US District Court of Delaware Ruled In Favor of Co. Related to Infringment Suit Against Hetero, InnoPharma, Hospira, Sagent Pharma, Accord Healhtchare",2016-06-10 14:22:00-04:00,EGRX,positive
413625.0,Teva Reports Favorable Court Ruling in TREANDA Infringement Case,2016-06-10 14:20:00-04:00,EGRX,neutral
413626.0,8 Biggest Mid-Day Gainers For Friday,2016-06-10 12:42:00-04:00,EGRX,neutral
413627.0,Benzinga Receives Document Confirming Positive Ruling For Eagle Pharmaceuticals In Treanda Case,2016-06-10 11:56:00-04:00,EGRX,positive
413628.0,Eagle Pharma Resumes; Now $53.77,2016-06-10 11:35:00-04:00,EGRX,neutral
413629.0,"Eagle Pharmaceuticals Up 27%, Shares Spiking",2016-06-10 11:35:00-04:00,EGRX,positive
413630.0,Eagle Pharmaceuticals Halted on CB at $45,2016-06-10 11:30:00-04:00,EGRX,neutral
413631.0,Watch These 5 Huge Call Purchases In Tuesday Trade,2016-06-07 00:39:00-04:00,EGRX,positive
413632.0,Option Alert: EGRX Jul16 40.0 Calls: 500 @  Above Ask!  $8.30: 500 traded vs 0 OI: $41.88 Ref,2016-06-06 14:48:00-04:00,EGRX,positive
413633.0,Option Alert: EGRX Jun16 25.0 Puts Sweep: 1141 @  ASK  $0.30: 1207 traded vs 625 OI: $46.54 Ref,2016-05-26 16:00:00-04:00,EGRX,positive
413634.0,Option Alert: EGRX Jun16 50.0 Calls: 500 @  ASK  $7.40: 1000 traded vs 938 OI: $49.89 Ref,2016-05-25 11:07:00-04:00,EGRX,positive
413635.0,Mid-Day Market Update: TETRA Technologies Drops Following Weak Results; Krispy Kreme Shares Spike Higher,2016-05-09 12:32:00-04:00,EGRX,negative
413636.0,Mid-Morning Market Update: Markets Edge Higher; Tyson Foods Tops Q2 Estimates,2016-05-09 09:55:00-04:00,EGRX,positive
413637.0,"Eagle Pharmaceuticals Reports Q1 EPS $(0.06) vs. Est. $(0.44), Rev. $29.6M vs. Est. $14.26M",2016-05-09 07:12:00-04:00,EGRX,neutral
413638.0,Eagle Pharma Announces CMS Determines that Existing J-Code J9033 Adequately Describes BENDEKA Injection,2016-04-20 06:54:00-04:00,EGRX,neutral
413639.0,Option Alert: EGRX Jun16 45.0 Calls Sweep: 760 @  ASK  $4.90: 760 traded vs 2241 OI:  Earnings 5/10  $39.99 Ref,2016-03-31 10:25:00-04:00,EGRX,positive
413640.0,Here's Why Eagle Pharmaceuticals Fell 7%,2016-03-28 11:05:00-04:00,EGRX,neutral
413641.0,Eagle Pharmaceuticals and the National Institutes of Health (NIH/NIDA) Enter into Agreement to Explore Use of Ryanodex in MDMA (Ecstasy) and Methamphetamine Intoxication,2016-03-28 07:01:00-04:00,EGRX,positive
413642.0,Eagle Pharma's Request for 7 Year Orphan Exclusivity for Bendeka Denied by FDA,2016-03-28 06:51:00-04:00,EGRX,negative
413643.0,FDA Letter to Eagle Pharma Says More Information is Needed for KANGIO NDA,2016-03-18 06:51:00-04:00,EGRX,neutral
413644.0,Option Alert: EGRX Jun16 50.0 Puts: 600 @  ASK  $7.50: 611 traded vs 77 OI:  Earnings 5/10  $54.16 Ref,2016-03-17 14:24:00-04:00,EGRX,positive
413645.0,"Eagle Pharma Reports Q4 EPS $0.07 vs $(0.39) in the Same Qtr. Last Year, Sales $18.2M vs $20.8M Est.",2016-02-25 06:58:00-05:00,EGRX,neutral
413646.0,Eagle Pharma Reports Received Sixth Patent for Bendamustine,2016-02-23 07:22:00-05:00,EGRX,neutral
413647.0,"Eagle Pharma Says Docetaxel Injection Commercially Available, Expects Annual Sales of $75M",2016-02-02 06:51:00-05:00,EGRX,neutral
413648.0,Eagle Pharma Announces FDA Granted Fast Track Designation to RYANODEX for Heat Strok,2016-02-01 06:50:00-05:00,EGRX,positive
413649.0,"8-K Filing From Eagle Pharmaceuticals Reports Teva Pharma Began Shipment Of BENDEKA, Coincides With Price Action Higher; However, Traders Believe Positive Note Circulating",2016-01-28 10:44:00-05:00,EGRX,positive
413650.0,Hearing Unconfirmed Market Chatter of Positive Note in Eagle Pharma,2016-01-28 10:42:00-05:00,EGRX,positive
413651.0,13G Filing Shows Eagle Pharma Holder Park West Asset Mgmt LLC Holds 5.1% Stake,2016-01-21 16:34:00-05:00,EGRX,positive
413652.0,Eagle Pharma Reports FDA Approval of Docetaxel Injection,2015-12-24 06:51:00-05:00,EGRX,positive
413653.0,The Top 20 Wall Street Analysts Of 2015,2015-12-17 10:44:00-05:00,EGRX,positive
413654.0,"Eagle Pharma Reports Successful Outcomes from Safety, Efficacy Study of RANODEX for Exertional Heat: 'Favorable Safety Data Shows No Significant Drug-Related Adverse Events'",2015-12-17 07:08:00-05:00,EGRX,positive
413655.0,The Five Best Biotech Analyst Calls Of 2015,2015-12-14 12:22:00-05:00,EGRX,positive
413656.0,"Mizuho Securities Initiates Coverage on Eagle Pharmaceuticals at Buy, Announces $112.00 PT",2015-12-09 09:13:00-05:00,EGRX,positive
413657.0,"Mizuho Securities Initiates Coverage on Eagle Pharmaceuticals at Buy, Announces $112.00 PT",2015-12-08 17:00:00-05:00,EGRX,positive
413658.0,Mid-Morning Market Update: Markets Tumble; AutoZone Profit Tops Estimates,2015-12-08 10:14:00-05:00,EGRX,positive
413659.0,Morning Market Gainers,2015-12-08 09:46:00-05:00,EGRX,neutral
413660.0,Eagle Pharma Announces Receiving $15M Milestone,2015-12-08 07:11:00-05:00,EGRX,neutral
413661.0,"Eagle Pharma. Achieves Milestone, Will Receive $15M For BENDEKA Approval; Company Looks Forward To Teva's Successful Commercialization Of New Treatment Option",2015-12-08 07:09:00-05:00,EGRX,positive
413662.0,"Eagle Pharma Announces Completion of Study For Ryanodex For Heat Stroke, Says Participants Showed no Drug Related Adverse Events",2015-10-06 07:05:00-04:00,EGRX,negative
413663.0,Eagle Pharmaceuticals Receives New Patent for Bendamustine Rapid Infusion Product,2015-09-29 08:03:00-04:00,EGRX,neutral
413664.0,"Eagle Pharma Reports Q2 Loss $0.53 Vs Est $0.57, Revs $6M vs Est $4.70M",2015-08-11 06:50:00-04:00,EGRX,negative
413665.0,Eagle Pharma Targets Hiked At Piper Jaffray On 'Room For Value Creation',2015-07-29 10:19:00-04:00,EGRX,positive
413666.0,Eagle Pharmaceuticals Announces FDA Accepts RTU Bivalirudin NDA for Filing,2015-07-23 07:10:00-04:00,EGRX,positive
413667.0,"Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says",2015-06-22 15:58:00-04:00,EGRX,neutral
413668.0,"RBC Capital Initiates Coverage on Eagle Pharmaceuticals at Outperform, Announces $97.00 PT",2015-06-22 07:38:00-04:00,EGRX,neutral
413669.0,"Cantor Fitzgerald Maintains Buy on Eagle Pharmaceuticals, Raises PT to $95.00",2015-06-16 07:46:00-04:00,EGRX,neutral
413670.0,Eagle Pharmaceuticals Submits NDA for Ready-to-Use Bivalirudin to FDA,2015-05-20 06:55:00-04:00,EGRX,neutral
413671.0,New Patent Issued for Eagle Pharmaceuticals' Bendamustine Rapid Infusion Product,2015-05-19 08:33:00-04:00,EGRX,neutral
413672.0,Eagle Pharma Q1 EPS $1.31 vs $1.47 est,2015-05-12 06:53:00-04:00,EGRX,neutral
413673.0,"Earnings Scheduled For May 12, 2015",2015-05-12 04:10:00-04:00,EGRX,neutral
413674.0,"Teva, Eagle Report NDA for Liquid Bendamustine Hydrochloride Rapid Infusion Product Has Been Accepted for Filing by FDA; PDUFA Date is December 2015",2015-04-14 08:07:00-04:00,EGRX,positive
413675.0,Benzinga's Volume Movers,2015-03-17 10:27:00-04:00,EGRX,neutral
413676.0,Eagle Pharmaceuticals Announces 1.320M Shares Price At $42.00/Share,2015-03-17 09:03:00-04:00,EGRX,positive
413677.0,Eagle Pharma Announces Offering Of 1.3M Shares At $42.00/Share,2015-03-17 09:01:00-04:00,EGRX,positive
413678.0,Eagle Pharma Announces Commencement of $50M Offering of Stock,2015-03-16 16:02:00-04:00,EGRX,neutral
413679.0,Eagle Pharmaceuticals Spiking Over $35,2015-02-23 10:26:00-05:00,EGRX,neutral
413680.0,UPDATE: FDA Grants 7 Year Market Exclusivity To Eagle Pharma Ryanodex,2015-02-23 10:25:00-05:00,EGRX,positive
413681.0,FDA Grants Seven Years' Market Exclusivity to Eagle Pharmaceuticals' Ryanodex for the Treatment of Malignant Hyperthermia,2015-02-23 10:24:00-05:00,EGRX,positive
413682.0,Benzinga's Volume Movers,2015-02-19 10:26:00-05:00,EGRX,neutral
413683.0,Benzinga's Volume Movers,2015-02-18 10:17:00-05:00,EGRX,neutral
413684.0,Stocks Hitting 52-Week Highs,2015-02-17 10:09:00-05:00,EGRX,neutral
413685.0,Morning Market Gainers,2015-02-17 09:43:00-05:00,EGRX,neutral
413686.0,"Teva, Eagle Pharmaceuticals Enter Exclusive License Agreement for EP-3102",2015-02-17 07:14:00-05:00,EGRX,positive
413687.0,Camber Capital Shows New 5.06% Passive Stake in Eagle Pharma,2015-02-02 11:56:00-05:00,EGRX,positive
413688.0,Eagle Pharmaceuticals Announces Change in Fiscal Year End,2015-01-20 09:20:00-05:00,EGRX,neutral
413689.0,"Eagle Pharmaceuticals Reports Positive Outcomes From Clinical Trial Of Bendamustine HCl Product Delivered Via Low-Volume, Rapidly Infused Admixture",2014-11-10 07:37:00-05:00,EGRX,positive
413690.0,"Shares of Eagle Pharma Just Resumed Following Circuit Breaker, Shares Now Down 13.6%",2014-10-15 10:03:00-04:00,EGRX,positive
413691.0,Eagle Pharmaceuticals Announces That Teva Requests a Motion to Dismiss with Prejudice in Its Bendamustine Patent Infringement Lawsuit ,2014-09-17 08:06:00-04:00,EGRX,negative
413692.0,Eagle Pharma Reports Q3 EPS of $(0.21) Which May Not Compare $(0.37) Est; Revenue of $5.80M Which May Not Compare $3.40M Est,2014-08-11 07:43:00-04:00,EGRX,neutral
413693.0,Eagle Pharma Reports Q3 EPS of $(0.21) vs $(0.37) Est,2014-08-11 07:31:00-04:00,EGRX,neutral
413694.0,"Earnings Scheduled For August 11, 2014",2014-08-11 05:30:00-04:00,EGRX,neutral
413695.0,Morning Market Movers ,2014-07-23 09:41:00-04:00,EGRX,neutral
413696.0,Benzinga's Top #PreMarket Gainers,2014-07-23 08:13:00-04:00,EGRX,positive
413697.0,US Stock Futures Rise Ahead Of Earnings,2014-07-23 07:40:00-04:00,EGRX,neutral
413698.0,FDA Approves Eagle Pharmaceuticals' Ryanodex For The Treatment Of Malignant Hyperthermia,2014-07-23 07:05:00-04:00,EGRX,positive
413699.0,Eagle Pharma Announces FDA Approval For Malignant Hyperthermia With Ryanodex,2014-07-23 07:05:00-04:00,EGRX,positive
413700.0,Eagle Pharmaceuticals Announces Orphan Drug Designation,2014-07-08 07:01:00-04:00,EGRX,neutral
413701.0,Eagle Pharma Shares Spiking Higher as Bloomberg Reporting Co. Has Received Orphan Drug Designation for Some Lymphomas,2014-07-07 13:03:00-04:00,EGRX,positive
413702.0,"Eagle Pharmaceuticals Receives Tentative Approval For Patented, Ready-To-Dilute Bendamustine Hydrochloride Injection NDA ",2014-07-02 12:33:00-04:00,EGRX,positive
413703.0,Eagle Pharma Reports Q2 EPS of $(0.36) vs $(0.26) Est; Revenue of $3.22M vs $3.20M Est,2014-05-14 06:54:00-04:00,EGRX,neutral
413704.0,Morning Market Movers ,2014-03-20 09:39:00-04:00,EGRX,neutral
413705.0,UPDATE: Eagle Pharmaceuticals Shares Rise 8% on Announcement of NDA for Ryanodex Being Accepted by FDA with Priority Review,2014-03-20 08:21:00-04:00,EGRX,positive
413706.0,Top Trending Tickers On StockTwits For March 10,2014-03-10 09:37:00-04:00,EGRX,positive
413707.0,Benzinga's Top Initiations,2014-03-10 08:41:00-04:00,EGRX,positive
413708.0,William Blair Initiates Coverage on Eagle Pharma at Outperform,2014-03-10 07:47:00-04:00,EGRX,neutral
413709.0,"Cantor Fitzgerald Initiates Coverage on Eagle Pharma at Buy, Announces $21.00 PT",2014-03-10 07:47:00-04:00,EGRX,neutral
413710.0,"Piper Jaffray Initiates Coverage on Eagle Pharma at Overweight, Announces $22.00 PT",2014-03-10 07:41:00-04:00,EGRX,negative
413711.0,Three IPOs Hit Wall Street on February 12,2014-02-13 11:58:00-05:00,EGRX,neutral
413712.0,"Shares of Eagle Pharma Open at $15.50/Share, Priced at $15",2014-02-12 10:26:00-05:00,EGRX,positive
413713.0,"Waiting on IPO Opens for Eagle Pharma at 10:25AM EST, Flexion Therapeutics at 10:50AM EST",2014-02-12 10:12:00-05:00,EGRX,neutral
